Biliting (bencycloquidium bromide pressurized metered dose inhaler) / YinGu Pharma - LARVOL DELTA

Chinese expert consensus on intranasal anticholinergics for allergic rhinitis. (PubMed, Asia Pac Allergy) - "Bencycloquidium bromide is a highly selective M1/M3 receptor antagonist that can reduce excessive mucus secretion and suppress type 2 inflammation in AR, while also demonstrating efficacy in alleviating overall nasal symptoms. In this consensus, we systematically review the role of acetylcholine and M receptors in AR pathogenesis, the key findings from clinical trials on intranasal anticholinergics for AR management and the evidence-based recommendations from experts in Allergy and Rhinology, hoping to guide physicians in the standardized and precise use of intranasal anticholinergics for AR patients."

Journal • Review • Allergic Rhinitis • Allergy • Immunology • Inflammation • Otorhinolaryngology

A Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled Trial for Effective and Safe of Bencycloquidium Bromide Nasal Spray in the treatment of Colds (ChiCTR) - P3 | N=480 | Completed | Sponsor: West China Hospital, Sichuan University; Silver Valley Pharmaceutical co., LTD

New P3 trial

A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis. (PubMed, Medicine (Baltimore)) - "The combination of BCQB and MNT had a greater overall effect, compared to MNT monotherapy in improving nasal symptoms such as nasal congestion and rhinorrhea, as well as quality of life in the treatment of (M/S)AR."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology

A Randomized Comparison of Bencycloquidium Bromide, Mometasone Furoate, and a Combination for Persistent Allergic Rhinitis. (PubMed, J Allergy Clin Immunol Pract) - P4 | "Bencycloquidium bromide was superior to MFNS in reducing daily runny nose symptoms. The combination of BCQB and MFNS was superior to MFNS alone in alleviating TNSS in patients with moderate to severe persistent AR with a predominant symptom of runny nose."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • CCL11 • IL6

Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis (clinicaltrials.gov) - P4 | N=450 | Active, not recruiting | Sponsor: Yingu Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2022 ➔ Jun 2024 | Trial primary completion date: Dec 2021 ➔ Apr 2024

Combination therapy • Enrollment closed • Trial completion date • Trial primary completion date • Allergic Rhinitis • Immunology • Inflammation

A multi-center observation of the therapeutic efficacy of Bencycloquidium bromide in the treatment of seasonal allergic rhinitis with predominant symptoms of rhinorrhea (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi) - "The incidence of adverse reaction was low and no serious adverse events occurred during the whole experiment. Bencycloquidium bromide nasal spray has significant efficacy and good safety in the treatment of seasonal allergic rhinitis."

Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology

Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis (clinicaltrials.gov) - P4; N=450; Recruiting; Sponsor: Yingu Pharmaceutical Co., Ltd

Clinical • Combination therapy • New P4 trial • Allergic Rhinitis • Immunology

Safety, Tolerability and Pharmacokinetics of Bencycloquidium Bromide, a Novel Inhaled Anticholinergic Bronchodilator, in Healthy Subjects: Results from Phase I Studies. (PubMed, Eur J Pharm Sci) - "The results of our study provided the initial safety, tolerability and pharmacokinetic profiles of BCQB inhalation, and could enable further clinical development in COPD patients."

Clinical • Journal • P1 data • PK/PD data • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Bencycloquidium bromide nasal spray is effective and safe for persistent allergic rhinitis: a phase III, multicenter, randomized, double-blinded, placebo-controlled clinical trial. (PubMed, Eur Arch Otorhinolaryngol) - "90 μg BCQB per nostril four times daily is effective and safe in the treatment of rhinorrhea as well as sneezing, nasal congestion and itching for patients with PAR."

Clinical • Journal • P3 data • Allergic Rhinitis • Immunology